Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous observation after ADR-001 in compensated liver cirrhosis
jRCT2033220602Completed
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of ADR-001 in Cirrhosis, sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Change in ALBI score. Started Feb 2023; status: completed.
02
Drugs
ADR-001
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on jRCT2033220602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033220602.